Panel Discussion: Alternatives to VC Funding in Financing Your Biomedical Company

Friday, August 2 2013
12:30 pm – 2:00 pm

Location: 300 TradeCenter, Suite 7400, Woburn – McLane Law


Panel discussion of Non-Venture Capital financing mechanisms including angels, strategic alliances, joint ventures, monetization of IP, grants and government awards.  The distinguished panel is comprised of a pharmaceutical executive managing its strategic investment and alliance fund, an angel and advisor to medical device companies (VC/Angel), and a CFO of a biomedical company having significant experience in raising non-dilutive financing and investment banking experience in the healthcare sector.   


Name: Reid J. Leonard, PhD

Title: Executive Director, Licensing and Managing Director of the Merck Research

         Ventures Fund (MRVF).

Company:  Merck

Bio:  For MRVF Dr. Leonard evaluates strategic alliances and direct fund investments in innovative therapeutics companies.  In 1998, he moved into the Merck External Scientific Affairs group where he has contributed to the search, evaluation, and execution of numerous biotech and academic partnerships to advance Merck’s pipeline.  Dr. Leonard joined Merck Research Laboratories, Rahway NJ, in 1989 and spent ten years at the bench practicing drug discovery.  Prior to his career in business development, Dr. Leonard conducted basic research and drug discovery on ion channels


Name: William D. McPhee, LLB

Title: Managing Partner

Company:  Praxis Advisors, LLC

Bio:  Mr. McPhee founded Praxis Advisors, a medical devices and technology consultancy. He has 30 years of experience in strategy consulting, venture capital and angel investing.  Mr. McPhee has raised over $150 million in risk capital, founded and exited two companies, and has extensive knowledge of medical devices, diagnostics, imaging and healthcare IT. He is an angel investor and is a member of Boston Harbor Angels and Mass Medical Angels.  Mr. McPhee has served as Director of Outsourced Business at Health Advances, Founder and Managing Director of Mi3 Venture Partners, Founder and Managing Director at Lucas McPhee & Company, Senior Consultant at Bain & Co., and as General Counsel for Pepsico – Canada.


Name: Thomas A. Fitzgerald

Title: Vice President and Chief Financial Officer (Interim CEO)

Company:  Velico Medical, Inc.

Bio:  Mr. Fitzgerald has served as Vice President and CFO of Velico Medical for seven years.  He is currently Interim President and CEO.  Mr. Fitzgerald has extensive financial management experience with life sciences companies as an investment banker and chief financial officer.  His specialty is improving corporate valuations through carefully considered strategic transactions and by close attention to operations, finance and day-to-day cash management.  As an investment banker, including as founding Managing Director for Healthcare at the Investment Banking firm of Leerink Swann, he completed public offerings, private financings, and mergers and acquisitions.  As CFO, he has improved working capital and cash flow, upgraded financial reporting systems and processes, improved operations, raised capital, and managed corporate governance, IT, facilities, and HR. 



Name: Steven R. London

Title: Partner in the Corporate and Securities Practice Group 

Company:  Pepper Hamilton LLP

Bio:  Steven R. London is a partner in the Corporate and Securities Practice Group of Pepper Hamilton LLP.  Mr. London concentrates his practice on corporate finance, securities and general corporate matters, and focuses on emerging growth and middle-market companies. For more than 30 years, Mr. London has assisted entrepreneurs in the growth and development of their business ventures. His activities include angel and venture capital financings, public and private equity and debt offerings, mergers and acquisitions and Securities and Exchange Commission compliance matters. He counsels boards of directors and senior management on corporate governance, shareholder activism and friendly and hostile M&A activity. 

Refreshments Served:   Pizza, salads, and soft-drinks

Cost for Members and Nonmembers,

  • Thanks to our host there is no charge for NSTC Members and Affiliates
  • $10.00 for Non-Members

Pre-register at

For more information, email

Host:  MedChem Partners provides services in all aspects of medicinal chemistry, from early stage hit generation, validation and proof-of-principle studies to late stage lead optimization. Their experience ranges from project inception and resource identification to synthetic route planning and library synthesis.  They can perform a variety of laboratory tasks from small and routine, such as lyophilization, LC/MS, NMR, salt switching, etc., to large and complicated, such as chemical modification of existing drugs or natural products, synthesis of reference compounds, generation of SAR series, or the like. Some of the medicinal chemistry services offered include: scaffold hopping, hit explosion, SAR development and lead generation, optimization of ADME, exploratory chemistry to validate synthesis of new scaffolds, metabolite and stable isotope synthesis, cold route finding in support of radiochemistry, and exploratory pre-formulation.  For more information visit



Share MassBio